title: Positron emission tomographic studies of dopa-responsive dystonia and early-onset idiopathic parkinsonism.
abstract: There are two major syndromes presenting in the early decades of life with dystonia and parkinsonism: dopa-responsive dystonia (DRD) and early-onset idiopathic parkinsonism (EOIP). DRD presents predominantly in childhood with prominent dystonia and lesser degrees of parkinsonism. EOIP presents before age 40 with parkinsonism (often with associated dystonia). Both disorders are exquisitely sensitive to levodopa, although the long-term prognosis in each appears to be different. Some have suggested, however, that DRD is a form of EOIP. We performed positron emission tomography with 6-fluoro-dopa in 10 patients with DRD and 18 patients with EOIP to study the integrity of their nigrostriatal dopaminergic systems. In DRD, we found normal striatal FD uptake. In contrast, patients with EOIP had reduced striatal FD uptake. We conclude that the patho-physiologies of DRD and EOIP are distinct. Although both disorders presumably represent a deficiency of striatal dopamine, the results suggest that in DRD dopa uptake, decarboxylation, and storage mechanisms are intact. This may explain the sustained response of DRD to low doses of levodopa. 6-Fluoro-dopa positron emission tomography distinguishes DRD from EOIP.
authors.affiliation: Neurodegenerative Disorders Centre, University of British Columbia, Vancouver, Canada.
authors.forename: B J
authors.initials: BJ
authors.lastname: Snow
authors.forename: T G
authors.initials: TG
authors.lastname: Nygaard
authors.forename: H
authors.initials: H
authors.lastname: Takahashi
authors.forename: D B
authors.initials: DB
authors.lastname: Calne
mesh_terms: D000293:Adolescent; D000328:Adult; D003342:Corpus Striatum / Q000000981:diagnostic imaging; D003937:Diagnosis, Differential; D004295:Dihydroxyphenylalanine / Q000031:analogs & derivatives*; D004421:Dystonia / Q000000981:diagnostic imaging* / Q000188:drug therapy; D005260:Female; D005462:Fluorine Radioisotopes; D006801:Humans; D007980:Levodopa / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D010300:Parkinson Disease / Q000000981:diagnostic imaging* / Q000188:drug therapy; D011379:Prognosis; D014055:Tomography, Emission-Computed
chemical_list: D005462:Fluorine Radioisotopes; C043437:fluorodopa F 18; D007980:Levodopa; D004295:Dihydroxyphenylalanine